Creating mRNA using E. coli bacteria
Official title: Producing Recombinant mRNA in Escherichia coli
Funded at E&e Bioclub LLC · NIH-11008720 · Data updated 2026-11-12
This study is working on a new way to make messenger RNA (mRNA) using E. coli bacteria, which could help produce mRNA more easily and affordably, so that patients can have better access to mRNA-based treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | E&e Bioclub LLC NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $300,518 |
| NIH project number | 1R43GM156257-01 |
| Project ID | NIH-11008720 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals who may require mRNA-based therapies, such as those with infectious diseases or genetic disorders.
✕Less likely to help
Patients who are not candidates for mRNA-based treatments or those with conditions that do not involve RNA therapeutics may not receive any benefit from this research.
What this research studies
This research focuses on developing a more efficient and cost-effective method for producing messenger RNA (mRNA) using E. coli bacteria. The approach aims to overcome current limitations in mRNA manufacturing, which often relies on expensive enzymes and reagents. By utilizing in vivo production methods, the research seeks to enhance the scalability and yield of mRNA, making it more accessible for therapeutic applications. Patients may benefit from improved availability of mRNA-based treatments as a result of this innovative manufacturing process.
Why it matters
Potential benefit: If successful, this research could lead to a more reliable supply of mRNA-based therapies, potentially improving treatment options for various diseases.
How similar studies have gone: Other research has shown promise in using bacterial systems for RNA production, indicating that this approach could be a viable solution for mRNA manufacturing challenges.
Where this research is happening
-
E&e Bioclub LLC
Indianapolis, United States Active
Researchers
- Principal investigator: Yu, Hao — E&e Bioclub LLC
- Study coordinator: Yu, Hao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.